CAMBRIDGE, Mass., Dec. 11 /PRNewswire/ -- Gwathmey, Inc., a pre-clinical contract research organization and biotechnology company specializing in cancer, staph aureus, and cardiovascular disease announces a new CEO. Gwathmey Pre-clinical Services announced today that Rosalie Dunn, Ph.D., has joined Gwathmey as Chief Executive Officer. Dr. Dunn has over 28 years of experience working with small businesses and the federal government. Prior to joining Gwathmey, Dr. Dunn managed multimillion dollar portfolios for the National Institutes of Health (NIH) which included cardiovascular devices and technologies, clinical studies, imaging applications, development of new animal models, bioengineering projects, sleep research, computer models, atherosclerotic plaque detection and classification, antiarrhythmic treatments and devices, telemetry systems and device miniaturization. While at the NIH she was Senior Scientific Administrator with the National Heart, Lung and Blood Institute (NHLBI). Dr. Dunn has held NIH-wide responsibility for developing, planning and managing small business programs. She received multiple NIH Awards of Merit as well as a Congressional Commendation for helping small businesses thrive. She has and continues to advise on statistical justification and design for experimentation, as well as formation of collaborations and partnerships between small businesses.
Dr. Dunn said "This difficult economy challenges smaller biotechnology as well as larger pharmaceutical companies, but at the same time it provides unique opportunities to forge new interrelationships that capitalize on niche expertise. In this case Gwathmey Inc. is in a prime position to provide individualized service economically and quickly. This is especially prominent in the cardiovascular and heart failure research area, as documented by Dr. Gwathmey's continued research supported by the NIH and her publications in medical research journals. It is my job to expand our strategic relationships and pursue new business initiatives for medical drug, treatment and device testing with a special emphasis in cardiovascular applications."
Dr. Dunn holds an appointment on the faculty of George Washington University Medical Center, Washington, D.C., where she continues as Adjunct Associate Professor in the Department of Computer Medicine.
Dr. Judith Gwathmey former CEO and Chief Scientific Officer for over 13 years stated "I am excited that Dr. Dunn has joined Gwathmey, Inc. She brings not only very strong business and leadership skills but also has an outstanding analytical mind. These attributes in combination with her well honed negotiating skills should result in the rapid establishment of effective and efficient working relationships with other businesses that incorporate speed and flexibility while remaining affordable and of the highest quality. Dr. Dunn represents the highest standards for quality and integrity in our industry. Having Dr. Dunn as CEO will enable me to devote greater efforts to the scientific aspects of Gwathmey, Inc.'s service portfolio that continues to grow at a rapid rate as well as manage our rapidly expanding services in the cardiovascular space."
Gwathmey, Inc. is a pre-clinical contract research organization that provides efficacy testing, safety, pharmacokinetic, early pharmacology and toxicology. For more information please visit our website at www.gwathmey.com.
SOURCE Gwathmey, Inc.
|SOURCE Gwathmey, Inc.|
Copyright©2009 PR Newswire.
All rights reserved